TrialPloS one2020

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.

Takeshi Onoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.